JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

Jazz Pharmaceuticals Public Limited Company is a global biopharmaceutical organisation dedicated to delivering life-changing medicines to patients who have limited or no treatment options. By unlocking scientific discoveries, the company develops novel therapies that enable people to live more fully, with a particular focus on oncology, neurology and rare disease areas.

The firm's pipeline includes HER2-targeted treatments for gastro-oesophageal adenocarcinoma, innovative combinations such as Ziihera® (zanidatamab-hrii), and specialised medicines for treatment-resistant epilepsy. Through extensive clinical-trial programmes and a commitment to patient-centred research, Jazz Pharma works closely with clinicians, caregivers and the wider medical community to bring new options to market and improve outcomes.

With a clear emphasis on innovation and real-world impact, Jazz Pharmaceuticals continues to expand its portfolio, share compelling data at international conferences and support families navigating complex health challenges, reaffirming its mission to transform lives and redefine what is possible.